Skip to main content

Diarrhoea Management using Over-the-counter Nutraceuticals in Daily practice (DIAMOND): a feasibility RCT on alternative therapy to reduce antibiotic use

A Correction to this article was published on 18 August 2021

This article has been updated



Although rarely indicated, antibiotics are commonly used for acute diarrhoea in China. We conducted a randomised, double blind exploratory clinical trial of loperamide, berberine and turmeric for treatment of acute diarrhoea.


Adults with acute uncomplicated diarrhoea aged 18 to 70 were randomised to 4 groups: (A) loperamide; (B) loperamide and berberine; (C) loperamide and turmeric; (D) loperamide, berberine and turmeric. All participants were given rescue ciprofloxacin for use after 48 h if symptoms worsened or were unimproved. Primary endpoints were feasibility and ciprofloxacin use during the 2-week follow-up period. Semi-structured interviews were conducted following recruitment and were analysed thematically. Recruiting doctors, delivery pharmacists and research assistants were blinded to treatment allocation.


Only 21.5% (278/1295) of patients screened were deemed eligible, and 49% (136/278) of these consented and were entered into the final analysis. Most participants had mild symptoms, because most patients with moderate or severe symptoms wanted to be given antibiotics. Follow-up was good (94% at 2 weeks). Only three participants used rescue antibiotics compared to 67% of acute diarrhoea patients in the hospital during the recruitment period. The median symptom duration was 14 h in group B (interquartile range (IQR) 10-22), 16 h in group D (IQR 10-22), 18 h in group A (IQR 10-33) and 20 h in group C (IQR 16-54). Re-consultation rates were low. There were no serious treatment-related adverse events. Most interviewed participants said that although they had believed antibiotics to be effective for diarrhoea, they were surprised by their quick recovery without antibiotics in this trial.


Although recruitment was challenging because of widespread expectations for antibiotics, patients with mild diarrhoea accepted trying an alternative. The three nutraceuticals therapy require further evaluation in a fully powered, randomised controlled trial among a broader sample.

Trial registration


Peer Review reports


What is already known about this subject

  • Unnecessary antibiotic use for acute diarrhoea is very common in primary care in China

  • Patients and doctors in China expect treatment for symptom relief

  • There are safe nutraceuticals already available for acute diarrhoea treatment

  • No study has evaluated if it is feasible to replace antibiotics with nutraceuticals for acute diarrhoea

What are the new findings

  • Patients and doctors found it acceptable to use alternatives to antibiotics but only for cases of mild diarrhoea

  • Loperamide, berberine and turmeric as alternative therapies allowed doctors to forego antibiotics in China for patients with mild diarrhoea, but require further evaluation in a fully powered randomised controlled trial

  • Conducting studies on reducing unnecessary antibiotic use in China is challenging

How might it impact on clinical practice in the foreseeable future

  • Provide a therapeutic alternative to antibiotics for acute diarrhoea management

  • After an adequately powered study, if shown to be effective, nutraceuticals could become standard therapy for managing acute diarrhoea


Acute diarrheal disease is still a major global burden [1,2,3]. Despite the limited benefit and potential harm from antibiotic use, acute diarrhoea is commonly treated with antibiotics in low- and middle-income countries (LMICs) [4,5,6]. Recent audits demonstrate that antibiotics are currently the standard treatment in many places in China [5]. There is a clear relationship between excessive antibiotic prescribing and antibiotic resistance [7, 8], which is a major threat to public health as new antibiotic drug development takes a long time and requires very significant investment [9]. China is one of the highest antibiotic consuming countries, with high rates of antibiotic resistance reported [10].

An effective non-antibiotic treatment for acute diarrhoea could relieve the pressure on Chinese doctors to prescribe antibiotics. Patients in primary care are often frustrated with the lack of effective interventions for self-limiting illnesses and a majority (72%) report that they expect to receive a prescription for something to help their symptoms [11], especially when they are poor and have spent precious resources to travel to see a doctor. Telling them that their problem will resolve spontaneously may lead to conflicts [12]. There is thus a significant incentive for Chinese doctors to prescribe something to meet patients’ expectations.

Non-antibiotic treatments for diarrhoea

Berberine is a natural product contained in many herbal medicines which are traditionally used for the treatment of diarrhoea [13]. It is likely to be effective in acute diarrhoea [14, 15], probably working through both antibacterial and anti-inflammatory effects, protecting against lipopolysaccharide induced intestinal injury by binding to TLR4/MD-2 receptors [16, 17]. Berberine use has been associated with changes in gut microbiota and an antidiarrheal effect [18]. Doses up to 400 mg daily were found to be effective in two trials in acute diarrhoea [14, 15, 19].

Curcumin (from turmeric) affects a range of cell modulating pathways and has antibacterial, antiviral, antioxidant and anti-inflammatory effects [20,21,22]. It is likely to be effective in diarrhoea of either infectious or non-infectious origin [21, 23,24,25]. One study of curcumin showed a rapid resolution of HIV-related diarrhoea [25] at a dose of 500 mg three times daily and doses up to 12000 mg per day have been used safely [23].

Loperamide not only is a widely used anti-motility agent but also acts synergistically with antibacterial agents [26]. A combination of berberine, turmeric and loperamide addresses a wide range of mechanistic pathways which are potential causes of acute diarrhoea.

Preliminary data and experience

Anecdotal experience with the combination of turmeric, berberine and loperamide for traveller’s diarrhoea has yielded dramatic results in 6 participants (DB, personal communication), faster than would be expected by loperamide alone [27]. All these agents are widely available over the counter, so this combination could provide an accessible treatment for acute diarrhoea globally and reduce inappropriate antibiotic use. However, although it is plausible that all three components are effective, it has not been clearly shown whether all three components are really needed for effective treatment. Before a fully powered trial can be justified, a smaller exploratory trial to document the feasibility and acceptability of using alternatives to antibiotics is warranted.

Objectives of this study

The primary feasibility objectives of this trial were:

  • To assess feasibility of recruitment

  • To assess retention and follow-up of recruited participants

  • To assess completion and return of symptom diaries

  • To identify barriers and facilitators to implement of this trial

The secondary patient-centred objectives were the following:

  • To estimate antibiotic use in intervention groups compared to usual care

  • To estimate the effect of combinations of nutraceuticals plus loperamide on duration and severity of acute diarrhoea

  • To estimate the incidence of side-effects in the intervention groups

Methods and analysis

The CONSORT extension statement checklist for pilot studies [28] was used as a guide to ensure complete and transparent reporting of our study (see Additional file 1).


Recruitment took place from 10th January to 30th September 2019, in a tertiary care hospital outpatient setting in China, where up to 75% of patients with acute diarrhoea are given antibiotics [4].

Outpatient clinical doctors screened participants’ eligibility during usual clinical consultations, then a researcher assistant introduced the trial to eligible participants, invited them to take part and obtained their consent. We included adults aged 18 to 70 presenting with acute diarrhoea, defined as at least 3 unformed stools in the previous 24 h, and with a duration of less than 7 days, without complications [29]. We excluded participants with vomiting as the most prominent symptom, visible blood in the stool, temperature greater than 39 degrees, suspected to have acute cholera or pseudomembranous colitis, who were immunocompromised, who had allergy to any of the proposed agents, symptom duration more than 7 days, pregnant women, patients with known chronic bowel disease, established ischaemic heart disease or a history of cardiac arrhythmias, and prolonged QT interval.


All recruiting doctors had packages, each of which had a unique computer-generated random study number together with a coded intervention group number prepared by the study statistician (BS), who was not involved in the implementation of group allocation. This package included a patient enrolment screening chart, consent information form, diary booklet, stool test form and medicine number. Each form was affixed with the study number. All these were prepared before recruitment was initiated. After recruitment, the participant went to the pharmacist who dispensed the corresponding medication pack. Onsite research assistants (RAs) were available to further answer questions for participants. Recruiting doctors, delivery pharmacists and research assistants were blinded to treatment allocation.


Each participant pack contained a 3-day supply of one of the following combinations, and each combination was to be used after each loose stool up to 3 times per day to continue until the diarrhoea stopped:

  • Group A, loperamide 4 mg initially then 2 mg following each loose stool, up to three times per day.

  • Group B, loperamide used as in group A and berberine100 mg up to four times daily following each loose stool.

  • Group C, loperamide used as in group A and turmeric 500 mg up to three times daily following each loose stool.

  • Group D, the combination of all 3 (loperamide, berberine and turmeric all as above).

A ‘rescue’ antibiotic (ciprofloxacin 750 mg stat) was given to be used only if symptoms were not starting to settle within 24 h, after telephone or face-to-face assessment by the designated doctor.

We included non-active nutraceuticals in the medication packs (amino acids) [30] for those individuals not receiving triple therapy so that every individual had three medication containers to use.


Loperamide was obtained from onsite hospital which was produced from Xi’an Janssen Pharmaceutical Co. Ltd. as 2 mg tablets. Berberine was obtained from onsite hsopital and it was from ReYoung Pharmaceutical Co. Ltd. as 100 mg tablets. Turmeric containing 6-8% curcumin was obtained from Nu U Nutrition, York, UK, as 500 mg capsules. Ciprofloxacin 750 mg was obtained from onsite hospital and it was from Shangdong Qilu Pharmaceutical Co. Ltd. Amino acid control tablets were obtained from Zhejiang CONBA Pharmaceutical Co. Ltd. CONBA G20120506 as 0.8 g/tablets.

Outcome measures

Primary feasibility outcomes

Feasibility outcomes included recruitment rate, exclusion rate and reasons, rejection rate and reasons, completion rate of the diary, compliance rate with the trial medications, withdrawal rate and follow-up rate. Patients were counted as lost to follow-up after three attempts at different time at each follow-up time. Each participant was asked to complete a daily symptom diary and compliance with the trial medications which has been used successfully in trials of medicines for diarrhoea [27]. The diary book recorded symptoms and medicines (medicines from trial and other resources) taken for 7 days starting from recruitment day 1 and asked to return at day 7. All participants were instructed to seek medical assistance again in the event that symptoms progressed. Follow-up was scheduled at 24 h (telephone, clinic visit if needed), 48 h (clinic visit), day 7 (clinic visit) and day 14 (telephone).

Secondary patient-centred outcomes

Exploratory outcomes included use of rescue antibiotics in 24 h, the duration of symptoms, the proportion with diarrhoea resolved at 24 h, and the severity of symptoms.

Use of antibiotics

We asked participants about antibiotic use including the “rescue” ciprofloxacin and any antibiotics from other sources through follow-up with doctors and phone calls from research assistants. This information was also recorded in the patient diary.

Severity of symptoms

The severity score was documented in the first 48 h because this is when symptoms are the most severe and nutraceuticals might make an important difference. The diary book recorded the number of stools during the previous 24 h for 7 days, the consistency of the last stool and the time since the last loose stool. The diary also recorded the severity of symptoms: diarrhoea, vomiting, nausea, abdominal pain, anal burning, fever, disturbed sleep, feeling generally unwell and interference with normal activities. Each symptom was scored on a Likert scale which has been shown to be valid and sensitive to change for a variety of infections, with up to 80% predictive sensitivity and more than 70% predictive specificity [31,32,33,34]. Scores ranged from 0 to 6: 0=no problem, to 6=as bad as it could be. Also documented was the duration of symptoms rated at least moderately bad (3) and the time taken for all symptoms to be rated as very little or no problem (1 or 0). Scores were grouped as 0-2 for mild, 3-4 for moderate and 5-6 for severe. A detailed severity and reporting process is provided in Additional file 2.

Incidence of side-effects

In the diary booklet, we asked participants to write down the potential side effects as below.

Do you think you may have had potential side effects of medication?

If yes, please specify ______________________________

Also, this question was listed in the follow-up with doctors and phone calls from research assistants. Potential side effects included constipation, skin rash and nausea.

Statistical analysis

Sample size estimation

In addition to feasibility outcomes, we aimed to recruit a sufficient sample to detect a difference between 50% using rescue antibiotics in the loperamide group and 15% in any other intervention group (for alpha 0.05 and 80% power), since 50% are likely to have resolved in 24 h [35, 36]. Assuming the median time for resolution in the loperamide group is 12 h (at the lower end of prior trial estimates [37]), we estimated that a sample of 30 per group with 1:1:1:1 ratio, which would allow us to detect a reduction in duration of loose stool to 8 h, or a hazard ratio of 2.1 with a slight over-enrolment to account for loss to follow-up.

All analyses were conducted following the intention-to-treat principle. All recruited cases were included, and there was no imputation of missing data. Descriptive statistics were used to report feasibility and clinical outcomes. Continuous variables were summarised as mean (sd) if normally distributed or median (range) for skewed data. Categorical data were summarised as counts and percentages. Descriptive statistics were used to describe side effects as total number, proportion and mean. If possible, multivariable regression analyses adjusting for number of loose stools at baseline, mean severity and prior duration were conducted for exploratory outcomes. Logistic regression was used for binary outcomes (antibiotic use and proportion with diarrhoea resolved at 24 h), linear regression was used for mean symptom severity, and Cox regression was used for duration until diarrhoea resolved, where possible. All analyses were performed using STATA 16 (Stata, College Station, TX, USA).

In-depth interviews

We conducted semi-structured qualitative interviews of patients and interviewed recruiting doctors and on-site research assistants after trial recruitment was completed. We planned to interview both patients who had declined to participate and those who had participated in the trial. We selected participants by study subject number and adjusted to ensure each group had a similar number of participants. Participants were invited to provide verbal consent. Interviews were conducted during the last week of recruitment by YJH. Face-to-face interviews were done on site. For patients who had completed follow-up and remained at home, we conducted telephone interviews. Interviews were discontinued once we reached data saturation. We aimed to understand which trial procedures did and did not work well, whether they were willing to recommend this therapy and suggestions for a future scale up study. Patients and doctors were also asked about what treatment they normally use for acute diarrhoea and whether they would be willing to recommend the trial therapy to others.


Primary feasibility outcomes


In total, 1296 patients were screened, 1160 were excluded and 136 were recruited. The majority of exclusions were either the doctor’s assessment that the patient was too severely unwell (57%) or the patients were already on antibiotics (9%) (Fig. 1).

Fig. 1

Consort report of patients’ pathway and the reasons for declined patients

Among the 278 eligible patients, 142 (51%) refused to participate (Fig. 2); 60 gave no reason (42%), 36 (25%) did not have time, 19 (13%) did not trust the trial medicines and 15 insisted on receiving an injection (11%). 13 were advised by family member not to join or insisted use antibiotics (9%).

Fig. 2

Proportion of excluded patients by reason

Diary completion

The overall diary completion and return rate was 92% (125/136) with no significant differences between the groups. The overall trial medicine compliance rates in total were 100% at day 1, 94% at day 2; 94% at day 3 and with similar rates to diary completion rates among 4 groups at day 7.

Baseline characteristics of recruited patients

Baseline characteristics are presented in Table 1. Overall, gender was fairly balanced across randomised groups. Most patients were young or middle-aged (mean 33 years, SD 12 years), and 39% were originally from Shanghai, whilst the rest had migrated there for work. The median number of loose stools in the last 24 h before treatment was 4 (IQR 4-5.5). Symptom severity was mild with an overall mean of 1.1 (sd 0.7) and was balanced across randomised groups. The response rate for baseline diarrhoea severity was high among 136 recruited participants, 125 (92%) recorded diarrhoea severity. Response rates for other baseline symptom items were lower: 69 (51%) reported abdominal cramping severity, 29 (21%) reported nausea severity and few patients (<10%) reported the remaining symptom items (vomiting, generally unwell, fever, muscle ache, headache, disturbed sleep, interference with normal activities, interference with social activities).

Table 1 Baseline characteristics


Follow-up rates were high, with 133 people (98%) followed up at 24 h, 131 (96%) at 48 h, 128 (94%) at 1 week, and 128 (94%) at 2 weeks. In total, there were 8 patients who withdrew or were lost to follow-up. Among those withdrawing, three were concerned with side effects from the trial medicines and 5 could not be reached after 24 h or 48 h (Fig. 3).

Fig. 3

Reasons for refusal to participate in the trial

Secondary patient-centred outcomes

Antibiotic use

Overall, only 3 participants took antibiotics during the study period. No patients in groups B (berberine + loperamide), C (turmeric + loperamide) or D (berberine and turmeric + loperamide) were advised by a recruitment doctor to take rescue antibiotics. Only 2 patients in group A (loperamide only) were advised to take rescue antibiotics. One person took rescue antibiotics in group C (loperamide and turmeric) without being advised to do so.

Effect of diarrhoea treatment on antibiotic use, duration and severity of symptoms

Crude outcomes along with adjusted estimates for antibiotic use, duration of diarrhoea, proportion of patients with diarrhoea resolved at 24 h and mean symptom severity during the first 48 h are presented in Table 2. There was no statistically significant difference in duration of diarrhoea between groups, nor in the proportion of patients reporting diarrhoea resolved at 24 h. Kaplan Meier curves for the duration of diarrhoea are presented in Fig. 4. The curves for group C (turmeric + loperamide) and D (berberine and turmeric + loperamide) cross the curve for group A (loperamide only), indicating that the proportional hazards assumption does not hold, so hazard ratios have not been calculated.

Table 2 Effectiveness of diarrhoea treatments on antibiotic use, duration and severity of symptoms
Fig. 4

Kaplan-Meier curves for duration of diarrhoea

Side-effects and re-consultations (Table 3)

No constipation was reported for groups B or C at 24 or 48 h. Constipation affected a small number of patients in groups A and D, and the mean severity of constipation at 24 and 48 h was mild. No rashes were reported at 24 or 48 h. There were very small numbers of unscheduled re-consultations and re-contacts.

Table 3 Side effects and re-consultation

Usual care for acute diarrhea

We extracted data from the hospital information system for all patients diagnosed with only acute diarrhoea without any comorbidities over the same time period. In total, 1367 patients in the same age range were analysed. There were 757 male (55%), and 610 female (45%) patients. Mean age was 41 years old. The antibiotic use rate in usual care overall during the study period was 67% (914/1367) whilst a rate of 2% (3/136) was observed in this trial. Further analysis showed that of patients receiving antibiotics in usual care, 64% (581/914) received these by injection. Of those given antibiotics, the majority (60%) received one antibiotic whilst 38% received two antibiotics and about 1.5% received more than 2 antibiotics. Sixty-three percent of them were given levofloxacin and 32% a 3rd generation cephalosporin.

Interview study

Of 30 participants approached, seven participants did not answer, six interviews could not be completed because of connectivity problems, three were too busy to be interviewed. Fourteen participants completed interviews. Of the patients who refused/declined to participate in the trial, none were willing to be interviewed. We interviewed six recruiting doctors (face-to-face) and six on-site researchers (3 by phone calls and three face to face as they were on site, Supplemental table). Interviews lasted an average of 30 min (range, 15-55 min). Thematic analysis [38] was employed for the transcripts. We identified three key themes in this study (Fig. 5). Table 4 shows the detailed quotes from interviews.

Fig. 5

Three themes from interviews

Table 4 Description of the themes from the interview

Factors facilitating use of nutraceuticals to manage acute diarrhoea and recruitment included the expectation for doctors to prescribe “something” to relieve symptoms. Both doctors and patients had very positive views on the effectiveness of the nutraceuticals. All interviewed patients and doctors expressed satisfaction with their treatment effects. Some patients even asked what those medications were and where to purchase them. Most interviewed patients felt that this trial had a flexible follow-up schedule and that the research assistants and doctors were friendly and provided very detailed explanations. Most of the doctors and RAs considered this trial was carefully designed and the concept was new.

However, there were also significant barriers to use of nutraceuticals to manage acute diarrhoea and to recruitment. Most patients believed antibiotics were “effective” for acute diarrhoea and most doctors would use antibiotics if patients “demand” them, as they worried about patients’ satisfaction and subsequent confrontation. All doctors and most RAs mentioned the doctor-patient relationship was a big barrier for trust. There were two arguments during the recruitment period. Half of the doctors would consider antibiotics for acute diarrhoea even without patients’ demands as they believed antibiotics are effective and shorten patients’ symptom duration. Doctors reported that they were initially suspicious of the anticipated effect as berberine and loperamide were commonly used previously and they did not feel they worked, whilst curcumin was familiar to them but they had not used it. However, positive patient feedback increased their confidence in this trial. One doctor reported that he started to recruit more patients with higher symptom scores after he observed that patients could accept the therapy and it was seen to be effective. Only two patients complained that turmeric capsules were too big to swallow. As there had not been a randomised trial like this before [19], doctors agreed that it was hard to tell whether these medicines would really work until they saw the results.

There were several suggestions for improving the trial’s processes for future studies. Although nine interviewed patients found that the diary was easy to use, four mentioned they could not carefully read and fully understand the diary and one suggested some wording changes. The stool samples were challenging to collect as it was difficult for patients to produce a stool on demand. Communication skills training was suggested by several doctors for on-site research assistants to allow them to communicate effectively with patients. All research assistants and doctors commented on the need for public awareness campaigns to reduce the demand for antibiotics and relieve the pressure on doctors. Five patients recommended better provision of information of the adverse effects of unnecessary antibiotic use. Ten patients reported that they wanted the public to benefit as that they were surprised that they did not expect to recover so quickly without antibiotics. All participants expressed their willingness to recommend this therapy to others and felt this was a meaningful trial and would support using the trial medication.


Summary of findings

Only 21% of patients screened for inclusion into this study were deemed to be eligible, and only half of those consented for study enrolment. The follow-up was excellent throughout; there was a very low rate of withdrawal and no safety concerns. Both doctors and patients were happy with the treatments and were willing to scale up or recommend to others. Most patients were happy with the diary and considered it easy to use, although some older patients found it more difficult. Blinding was successful.

The main barriers to recruitment are the strong belief that antibiotics are effective for the treatment of acute diarrhea and the often fraught doctor patient relationship in China. Doctors fear patient dissatisfaction and find it difficult to avoid the deeply entrenched routine of using injections and injectable antibiotics. During consultations many patients requested injections and antibiotics, increasing pressure on doctors to comply, and one patient complaint was only resolved by involving a local policeman.

Although this feasibility study was not powered to detect a difference between groups in the time to recovery, this study does provide support for a larger trial to document the effective use of alternatives to antibiotics for the treatment of acute diarrhoea in China. Although antibiotics are not recommended for diarrhea, they are commonly used in many places especially in LMICs [39,40,41]. Only 2% (3/136) of participants used antibiotics, in contrast to the 67% of the patients in routine care at the same hospital during the study period, when more than 60% of the prescribed antibiotics were given by injection, although the symptom severity is difficult to compare without a randomly assigned usual care control group. However, all usual care data came from patients diagnosed with acute diarrhoea without co-morbidity within the same age range during the same recruitment period. Up to 50% were eligible for inclusion but refused to participate in the trial.

Comparison with the existing literature

There have been few well-designed studies on traditional Chinese medicines (TCM) as alternatives to antibiotics for relief of symptoms for acute diarrhoea [42, 43]. Many of those trials were with small sample size, majority of the trials were considered high risk of bias, mainly due to unclear concealment and no blinding [1]. Trial insurance requirements were only recently launched in China [44, 45] as one of the doctors mentioned that it was the first time he had seen a trial covered by insurance.

This feasibility study has provided evidence that it is possible to implement a trial like this in China in spite of the recruitment challenges observed. Other studies have also shown similar antibiotic use rates in China [46] despite the expansion of antibiotic stewardship in hospitals and the National Action Plan on containing antimicrobial resistance in 2016 [47]. One national survey on the antimicrobial stewardship programme (ASP) mentioned that although more than 65% of doctors were familiar with the ASP, only 46% of them had correct answers with ASP test [48]. This indicates the urgent need for further training for doctors.

Strengths and Limitations

This is the first feasibility trial investigating the use of nutraceuticals to treat acute diarrhoea in China. A strength of this study is that we used both quantitative and qualitative methods to explore and more deeply understand the recruitment challenges. The interviews shed light on the underlying reasons for the observed high refusal rate and the suggestions from this interview study will be invaluable for future scaling up of studies in China. Although the study was under-powered to compare the effectiveness of each nutraceutical, each treatment resulted in symptoms resolving rapidly, and most patients and doctors felt the treatments were effective.

This study has limitations. First, most of the recruited patients experienced very mild symptoms [29]. We were unable to interview any of the patients who refused consent to participate. As discussed above, recruitment may have been influenced by the doctors’ complex relationship with patients in China [12]. Many of the recruited patients were young with a college education level, who might be expected to have lower expectations for antibiotics. We also did not systematically collect stool samples to determine whether bacterial, parasitic or viral infections were present; this was originally planned, but proved logistically difficult in the outpatient setting as patients were mostly unable to provide a stool specimen at the time of consultation.

Implications for policy, practice and further research

Our results suggest that progression to a full randomised trial is feasible. Adequate onsite support will be needed as doctors are very busy and many lack research experience. Minor modifications will be needed to the diary to make it clearer and easier to complete though the completion rate was high (92%). The evidence that patients recovered within 48 h without antibiotics can be used to help doctors and patients accept using alternatives to antibiotics. Although no formal progression criteria were set at the start of this trial or written into the study protocol, the feasibility of a definitive trial was assessed against the objectives as set out in Table 5 alongside the data collected in the qualitative study.

Table 5 Feasibility objectives and endpoints of Diamond study

From this study, we learnt that antibiotics were commonly used for acute diarrhoea in usual care in clinic (67%), which were often provided because of the doctors’ belief in the effect of antibiotics for acute diarrhoea and the long-established practice in using antibiotics, or the anxiety related to patient demands. This indicates that antibiotic stewardship programmes are urgently needed in many hospitals and clinics to address over-use of antibiotics especially for those with acute diarrhoea in China. Effective alternatives to antibiotics are likely to be an important intervention for these patients. A large fully powered trial is needed to define the effectiveness by comparing placebo, loperamide, berberine and loperamide + berberine in a wider range of patients with acute diarrhoea in China.


Recruitment of patients with anything other than mild diarrhoea was very challenging in the current clinical environment in China. However, patients reported their symptoms recovered quickly. Patients need better information on the adverse effects of unnecessary antibiotic use. Use of loperamide and berberine may relieve symptoms as a viable alternative to antibiotics. This approach should be scaled up for further evaluation in a randomised controlled trial to investigate its effectiveness.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Change history



Diarrhoea Antibiotic Management using Over-the-counter Nutraceuticals in Daily practice


Randomised controlled trial


The World Health Organisation


Traditional Chinese medicines




  1. 1.

    Das JK, Bhutta ZA. Global challenges in acute diarrhea. Curr Opin Gastroenterol. 2016;32(1):18–23.

    Article  Google Scholar 

  2. 2.

    Carlton EJ, Woster AP, DeWitt P, Goldstein RS, Levy K. A systematic review and meta-analysis of ambient temperature and diarrhoeal diseases. Int J Epidemiol. 2016;45(1):117–30.

    Article  Google Scholar 

  3. 3.

    Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81(3):197–204.

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Hu Y, Wang S, Hua S, Willcox M, Moore M, Little P. Antibiotic prescription patterns for acute diarrhea in a hospital in Shanghai in 2016: a cross-sectional study. Open Forum Infect Dis. 2017;4(Suppl 1):S326.

    Article  Google Scholar 

  5. 5.

    Suy S, Rego S, Bory S, Chhorn S, Phou S, Prien C, et al. Invisible medicine sellers and their use of antibiotics: a qualitative study in Cambodia. BMJ Global Health. 2019;4(5):e001787.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Carter E, Bryce J, Perin J, Newby H. Harmful practices in the management of childhood diarrhea in low- and middle-income countries: a systematic review. BMC Public Health. 2015;15(1):788.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7. 2014 (Accessed 27.08.2015 2015).

  8. 8. 2012 (Accessed 26.08.2015 2015).

  9. 9.

    Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy. 2017;121(10):1025–30.

    Article  Google Scholar 

  10. 10.

    Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A. 2018;115(15):E3463–E70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Davis ME, Liu T-L, Taylor YJ, Davidson L, Schmid M, Yates T, et al. Exploring patient awareness and perceptions of the appropriate use of antibiotics: a mixed-methods study. Antibiotics. 2017;6(4):23.

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    The L. Violence against doctors: why China? Why now? What next? Lancet. 2014;383:9922.

    Google Scholar 

  13. 13.

    Chander V, Aswal J, Dobhal R, Uniyal D. A review on pharmacological potential of berberine; an active component of Himalayan Berberis aristata. J Phytopharmacol. 2017;6(1):53–8.

    Google Scholar 

  14. 14.

    Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis. 1987;155(5):979–84.

    CAS  Article  Google Scholar 

  15. 15.

    Khin Maung U, Myo K, Nyunt Nyunt W, Aye K, Tin U. Clinical trial of berberine in acute watery diarrhoea. Brit Med J. 1985;291(6509):1601–5.

    Article  Google Scholar 

  16. 16.

    Chu M, Ding R, Chu ZY, Zhang MB, Liu XY, Xie SH, et al. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. BMC Complement Altern Med. 2014;14(1):89.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Li HM, Wang YY, Wang HD, Cao WJ, Yu XH, Lu DX, et al. Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptor-independent mechanisms. Acta Pharmacol Sinica. 2011;32(11):1364–72.

    CAS  Article  Google Scholar 

  18. 18.

    Habtemariam S. Berberine and inflammatory bowel disease: a concise review. Pharmacol Res. 2016;113(Pt A):592–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Yu M, Jin X, Liang C, et al. Berberine for diarrhea in children and adults: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2020;13:1756284820961299.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int. 2014;2014:186864.

    Article  Google Scholar 

  21. 21.

    Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Curr Pharm Des. 2013;19(11):2032–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Hewlings SJ, Kalman DS. Curcumin: a review of its’ effects on human health. Foods. 2017;6(10):92.

    Article  Google Scholar 

  23. 23.

    Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.

    CAS  Article  Google Scholar 

  24. 24.

    Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012;85(4):249–55.

    CAS  Article  Google Scholar 

  25. 25.

    Conteas CN, Panossian AM, Tran TT, Singh HM. Treatment of HIV-associated diarrhea with curcumin. Dig Dis Sci. 2009;54(10):2188–91.

    CAS  Article  Google Scholar 

  26. 26.

    Ejim L. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol. 2011;7:348–50.

    CAS  Article  Google Scholar 

  27. 27.

    Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol. 2005;11(10):1540–3.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasib Stud. 2016;2(1):64.

    Article  Google Scholar 

  29. 29.

    Riddle MS, DuPont HL, Connor BA. ACG clinical guideline: diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602–22.

    CAS  Article  Google Scholar 

  30. 30.

    Černá M. Seaweed proteins and amino acids as nutraceuticals. Adv Food Nutr Res. 2011;64:297–312.

    Article  Google Scholar 

  31. 31.

    Watson L, Little P, Williamson I, Moore M, Warner G. Validation study of a diary for use in acute lower respiratory tract infection. Fam Pract. 2001;18(5):553–4.

    CAS  Article  Google Scholar 

  32. 32.

    Little PS, Williamson I, Warner G, Gould C, Gantley M, Kinmonth AL. An open randomised trial of prescribing strategies for sore throat. BMJ. 1997;314(7082):722–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Little P, Hobbs FDR, Moore M, et al. PRImary care Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic adaptive randomised controlled trial with nested qualitative study and cost-effectiveness study. Health Technol Assess. 2014;18(6):1–101.

    Article  Google Scholar 

  34. 34.

    Little P, Turner S, Rumsby K, et al. Urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. Health Technol Assess. 2009;13:19.

    Article  Google Scholar 

  35. 35.

    Das JK, Bhutta ZA. 3.6 Reducing the burden of acute and prolonged childhood diarrhea. World Rev Nutr Diet. 2015;113:168–72.

    Article  Google Scholar 

  36. 36.

    Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47(1):12–20.

    Article  Google Scholar 

  37. 37.

    Barr W, Smith A. Acute diarrhea. Am Fam Physician. 2014;89(3):180–9.

    Google Scholar 

  38. 38.

    Chapman A, Hadfield M, Chapman C. Qualitative research in healthcare: an introduction to grounded theory using thematic analysis. J Royal College Physicians Edinburgh. 2015;45(3):201–5.

    CAS  Article  Google Scholar 

  39. 39.

    Li R, Xiao F, Zheng X, Yang H, Wang L, Yin D, et al. Antibiotic misuse among children with diarrhea in China: results from a national survey. PeerJ. 2016;4:e2668.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Efunshile AM, Ezeanosike O, Nwangwu CC, König B, Jokelainen P, Robertson LJ. Apparent overuse of antibiotics in the management of watery diarrhoea in children in Abakaliki, Nigeria. BMC Infect Dis. 2019;19(1):275.

    Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Jones T. Overutilization of antibiotics in children with diarrhea: first do no harm. Clin Infect Dis. 2017;66(4):512–3.

    Article  Google Scholar 

  42. 42.

    Li DY, Dai YK, Zhang YZ, Huang MX, Li RL, Ou-yang J, et al. Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome. PLoS One. 2017;12(12):e0189491.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Yu M, Jin X, Liang C, Bu F, Pan D, He Q, et al. Berberine for diarrhea in children and adults: a systematic review and meta-analysis. Ther Adv Gastroenterol. 2020;13:1756284820961299.

    Google Scholar 

  44. 44.

    Xu J, Li B, Ma Q, Liu HH, Cong Y. Human subjects protections in clinical drug trials in China. Int J Pharm Med. 2006;20(6):367–72.

    Article  Google Scholar 

  45. 45.

    Partners F. Preclinical and clinical trial requirements: China. 2019. (Accessed 0908 2020).

  46. 46.

    Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174:1914–20.

    Article  Google Scholar 

  47. 47.

    Wang S, Hu YJ, Little P, Wang Y, Chang Q, Zhou X, et al. The impact of the national action plan on the epidemiology of antibiotic resistance among 352,238 isolates in a teaching hospital in China from 2015 to 2018. Antimicrob Resist Infect Control. 2019;8(1):22.

    Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Xia R, Hu X, Willcox M, Li X, Li Y, Wang J, et al. How far do we still need to go? A survey on knowledge, attitudes, practice related to antimicrobial stewardship regulations among Chinese doctors in 2012 and 2016. BMJ Open. 2019;9(6):e027687.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We thank all the patients to take part in this study. Shanghai Jiading District Central Hospital leaders support. The doctors from Jiading District Central Hospital for the recruitment. The research team from Zhejiang University and Diamond study group. The turmeric capsules used in the study were kindly donated by Nu U Nutrition, York, UK. We would like to acknowledge the early contributions from Professor George Lewith, we remember and are grateful for his lifetime of contributions to medical research.


This project was supported by a grant from Antibiotic Research UK and Prof David Brown personally. The salary of MLW was funded by the National Institute of Health Research (NIHR), under grant CL-2016-26-005. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author information




Conception: YJH and PL conceived the study idea, DB conceived the intervention therapy. TF and BS analysed the data. YJH, XDZ and SJW, ZRH, QC contributed to the implementation and data collection. YJH and PL drafted the manuscript. MW, YJH, PL, DB, CG, XZ and MM revised the protocol and manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Yanhong Jessika Hu.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was first obtained by the WHO China Clinical Trials Central Medical Ethics Committee. Reference No: ChiECRCT-2017098. We also obtained the ethical approval from the medical ethics committee of the implementing hospital Shanghai Jiading District Centre Hospital. Reference No: 201802.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: the abbreviated author’s name JYH should be updated to YJH.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hu, Y.J., Zhou, X., Wang, S. et al. Diarrhoea Management using Over-the-counter Nutraceuticals in Daily practice (DIAMOND): a feasibility RCT on alternative therapy to reduce antibiotic use. Pilot Feasibility Stud 7, 126 (2021).

Download citation


  • Diarrhoea
  • Antibiotic management
  • Over-the-counter
  • Nutraceuticals
  • Feasibility RCT
  • Alternative therapy
  • Turmeric (curcumin-active ingredient)